Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical leader pioneering engineered antibody therapeutics for cancer and autoimmune diseases through its proprietary XmAb® technology platform. This page serves as the definitive source for tracking Xencor's latest developments, providing investors and industry observers with timely updates on scientific advancements and business milestones.
Access comprehensive coverage of Xencor's clinical trial progress, regulatory updates, and strategic collaborations with global pharmaceutical partners. Our curated news collection features verified press releases and analysis-worthy developments including technology licensing agreements, pipeline expansions, and research breakthroughs in antibody engineering.
Key content focuses include updates on XmAb® platform innovations, partnership announcements with major drug developers, clinical study results for novel cancer treatments, and progress in autoimmune therapy candidates. All content is rigorously vetted to ensure relevance to investment decision-making and scientific credibility.
Bookmark this page for streamlined access to Xencor's evolving story in biotherapeutic innovation. Check regularly for critical updates on therapeutic candidates moving through clinical development phases and new applications of its protein engineering expertise.
Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.
- Bernstein CD28 Day: Presentation on August 9 at 1:00 p.m. ET.
- Wedbush PacGrow Healthcare Conference: Panel on August 10 at 1:10 p.m. ET.
- BTIG Virtual Biotechnology Conference: Presentation on August 10 at 3:30 p.m. ET.
- Canaccord Genuity Conference: Presentation on August 11 at 4:30 p.m. ET.
- Piper Sandler West Coast Bus Tour: Presentation on August 12 at 4:00 p.m. ET.
A webcast of the Canaccord presentation will be available on Xencor's website.
Xencor, Inc. (NASDAQ: XNCR) will release its second quarter 2021 financial results post-market on August 4, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. The live call can be accessed via phone or a webcast on the company's website. Xencor is a clinical-stage biopharmaceutical firm focusing on engineered monoclonal antibodies and cytokines targeting cancer and autoimmune diseases, with 22 candidates in clinical development leveraging its XmAb® technology.
Xencor, Inc. (NASDAQ: XNCR) announced that Dr. Bassil Dahiyat, president and CEO, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. ET. The presentation will cover Xencor's focus on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases. A webcast of the event will be available on the company's website, with a replay accessible for at least 30 days following the event.
Xencor, Inc. (NASDAQ: XNCR) announced that the FDA has granted emergency use authorization for sotrovimab, an engineered monoclonal antibody developed with Vir Biotechnology and GlaxoSmithKline to treat mild-to-moderate COVID-19 in high-risk patients. While not approved, sotrovimab shows an 85% reduction in hospitalization or death based on Phase 3 trial data. Xencor has licensed its Xtend technology to Vir to enhance antibody performance. The EUA will last as long as the COVID-19 emergency declaration is in effect.
Xencor, a clinical-stage biopharmaceutical company (NASDAQ:XNCR), entered a licensing agreement with Bristol-Myers Squibb (NYSE:BMY) for its Xtend™ Fc technology to extend the half-life of the SARS-CoV-2 mAb Duo, designed for COVID-19 treatment. This antibody combination, discovered at Rockefeller University, is currently in Phase 1 clinical evaluation. Xencor, eligible for royalties from sales, emphasizes that its technology improves therapeutic performance, potentially lowering costs for antiviral therapies. The partnership aims to address urgent medical needs, particularly in the pandemic context.
Xencor, a clinical-stage biopharmaceutical company focusing on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced that its CEO, Bassil Dahiyat, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference. The event is set for May 19, 2021, at 1:20 p.m. ET. Investors can access a live webcast on the company's website, with a replay available for 30 days afterward. Xencor has 21 clinical candidates utilizing its XmAb technology.
Xencor, a clinical-stage biopharmaceutical company, reported Q1 2021 financial results, achieving a total revenue of $34 million, an increase from $32.4 million in Q1 2020. The net loss narrowed to $2.5 million or $(0.04) per share, compared to a loss of $8.1 million the previous year. Cash and equivalents amounted to $577.1 million. Recently, Xencor initiated a Phase 1 study for XmAb564 and presented preclinical data at the AACR meeting. Future clinical studies are planned for XmAb717 and Tidutamab.
Xencor, Inc. (NASDAQ: XNCR) has initiated a Phase 1 clinical study for XmAb564, targeting autoimmune diseases. The first subject has been dosed in this randomized, double-blind, placebo-controlled trial, which evaluates the safety and tolerability of XmAb564 in healthy volunteers. XmAb564 is designed to selectively activate regulatory T cells while minimizing activation of other immune cells, aimed at improving therapeutic outcomes. Preliminary studies indicate it has favorable pharmacologic properties and promotes sustained Treg proliferation.
Xencor, Inc. (NASDAQ: XNCR) announced its plans to release first quarter 2021 financial results after market close on May 5, 2021. A conference call will be held the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the call by dialing (877) 359-9508 or through an online webcast available on Xencor's website. The company is focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune disease treatments, with 21 candidates in clinical development.
Xencor, Inc. (NASDAQ:XNCR) announced new data presentation from its preclinical bispecific antibody and IL-12-Fc cytokine programs at the AACR Annual Meeting. The data showcases the potential of CD28 and XmAb 2+1 platforms, emphasizing their engineered cytokines' enhanced therapeutic indices. Notably, Xencor plans to submit an IND for their XmAb819 bispecific antibody in 2021 and start a Phase 1 study in early 2022. The IL-12-Fc fusions showed significant anti-tumor activity in preclinical models, indicating a promising future for Xencor's innovations in cancer therapies.